Otsuka Pharmaceutical Reports P-III (VISIONARY) Trial Data on Voyxact for IgA Nephropathy (IgAN)

Why It Matters

Voyxact’s ability to rapidly clear hematuria and potentially slow eGFR decline could become the first disease‑modifying therapy for IgAN, addressing a major unmet need in nephrology.

Key Takeaways

• 82.5% achieved negative hematuria vs 52.6% placebo.
• Median time to hematuria remission: 9 weeks vs 24 weeks.
• Voyxact targets APRIL inhibition for IgAN treatment.
• Phase III VISIONARY trial assesses 24‑month eGFR slope.
• Data presented at ISN World Congress 2026.

Pulse Analysis

IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide, often leading to chronic kidney disease and end‑stage renal failure. Current management relies on nonspecific blood pressure control and immunosuppression, which carry safety concerns and limited efficacy. The disease is driven by aberrant mucosal immunity, with elevated APRIL (a proliferation‑inducing ligand) promoting pathogenic IgA production. Targeting APRIL therefore represents a mechanistic approach to curb immune‑mediated injury, and Otsuka’s sibeprenlimab‑szsi (Voyxact) is the first antibody designed to inhibit this pathway. Given the disease's prevalence of 2–3 % in many populations, any therapeutic advance carries substantial public‑health relevance.

The Phase III VISIONARY trial enrolled patients at high risk of progression and compared monthly subcutaneous Voyxact 400 mg to placebo. At 48 weeks, 82.5 % of treated participants achieved negative microscopic hematuria (0–5 /HPF) versus 52.6 % on placebo, and the median time to reach this threshold was cut from 24 to 9 weeks. Hematuria reduction correlates with lower proteinuria and slower eGFR decline, suggesting Voyxact may preserve kidney function. The study will continue to monitor eGFR slope over a 24‑month period to confirm long‑term benefit. Patient‑reported outcomes also improved, reflecting reduced disease burden and better quality of life.

If the eGFR data confirm a meaningful slowing of renal decline, Voyxact could become the first disease‑modifying therapy approved for IgAN in the United States, a market projected to exceed $1 billion globally. Otsuka’s data, presented at the ISN World Congress of Nephrology, position the company ahead of competitors still relying on steroids or nonspecific immunosuppressants. A positive regulatory outcome would also validate APRIL inhibition as a viable target, potentially spurring additional biotech investment in similar biologics. Stakeholders should watch upcoming FDA filings and real‑world evidence as the trial matures.